CSIMarket
 
Eagle Pharmaceuticals inc   (NASDAQ: EGRX)
 
Price: $0.9250 $0.00 0.000%
Day's High: $0.925000011920929 Week Perf: 74.53 %
Day's Low: $ 0.93 30 Day Perf: 150 %
Volume (M): 0 52 Wk High: $ 0.93
Volume (M$): $ 0 52 Wk Avg: $0.17
Open: $0.93 52 Wk Low: $0.00



 Market Capitalization (Millions $) 12
 Shares Outstanding (Millions) 13
 Employees 117
 Revenues (TTM) (Millions $) 258
 Net Income (TTM) (Millions $) 12
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 0

Business Description


Eagle Pharmaceuticals Inc. is a specialty pharmaceutical company that is headquartered in Woodcliff Lake, New Jersey, United States. The company was founded in 2007, and it operates as a subsidiary of Eagle Parent Holdings LLC. It is involved in the development and commercialization of injectable drugs that address unmet medical needs.

Eagle Pharmaceuticals focuses on drugs that are difficult to administer or have a limited shelf life. The company's products are designed to improve the safety, efficacy, and convenience of existing therapies. The company has a dedicated research and development team that works on developing the most innovative drugs.

The company's portfolio of products includes injectable drugs for critical care, oncology, and orphan diseases. Among its most notable products are Ryanodex, a treatment for malignant hyperthermia, and Bendeka/Benqim, a treatment for chronic lymphocytic leukemia. Additionally, it offers injectable drugs for the treatment of pain, infections, and rheumatoid arthritis.

Eagle Pharmaceuticals' business model is based on licensing, developing, and partnering with other pharmaceutical companies to market and distribute its products. The company's primary target is the United States market, but it has operations in Europe, the Middle East, and Asia as well. Its products are marketed through a network of distributors and partners.

The company has partnerships with several pharmaceutical companies, including Teva, Lupin, and Dr. Reddy's Laboratories. Eagle Pharmaceuticals has also established partnerships with academic medical centers and research organizations to advance its drug development program.

In conclusion, Eagle Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of injectable drugs for difficult-to-treat medical conditions. Its innovative products are aimed at improving the safety, effectiveness, and convenience of existing therapies. The company is committed to building strong partnerships with other companies and research organizations to advance its drug development program.


   Company Address: 50 Tice Boulevard Woodcliff Lake 7677 NJ
   Company Phone Number: 326-5300   Stock Exchange / Ticker: NASDAQ EGRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ENDPQ     
HZNP        0.46% 
PFE        1.75% 
PRGO        2.59% 
TEVA   -2.38%    
VTRS   -0.18%    
• View Complete Report
   



Contract

Eagle Pharmaceuticals Ventures into Financial Strategy $69 Million Royalty Agreement for BENDEKA Highlights Innovat...

Published Tue, Apr 1 2025 5:00 AM UTC

Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX), based in Woodcliff Lake, New Jersey, has announced a significant transaction aimed at enhancing its financial standing. On March 31, 2025, the company entered into a royalty purchase agreement to monetize its royalty interest in the annual net sales of BENDEKA (bendamustine hydrochloride injection), a drug utilized in the treatmen...

Shares

Eagle Pharmaceuticals Takes Proactive Measure with Limited Duration Stockholder Rights Plan Amid Nasdaq Delisting Concerns

Published Thu, Oct 31 2024 12:00 PM UTC

In a strategic move to safeguard its shareholders and enhance corporate governance, Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX), based in Woodcliff Lake, N.J. announced today that its Board of Directors has adopted a limited duration stockholder rights agreement. This Rights Plan, effective immediately as of October 31, 2024, comes at a crucial time for the company as it fac...

Stock Market Announcement

Delisting Process Initiated for Eagle Pharmaceuticals Inc. on Nasdaq: Impact on Shareholders and Stock Price

Published Wed, May 22 2024 1:00 PM UTC

Delisting Process Initiated for Eagle Pharmaceuticals Inc. on Nasdaq: Impact on Shareholders and Stock Price
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) has recently received a notice from Nasdaq regarding the initiation of a delisting process due to the Company s failure to file its necessary financial reports. This news comes after a previous notification of deficiency ...

Clinical Study

Bolstering the Future of Postoperative Care: Eagle Pharmaceuticals Showcases Promising Data on Amisulpride's Sustained Response for Postoperative Nausea and Vomiting Rescue

Published Mon, Apr 15 2024 11:00 AM UTC

Eagle Pharmaceuticals, a leading entity in the biomedicine space, is set to present supplementary data from their consequential Phase III trial at the revered ASPAN 2024 National Conference, scheduled to be orchestrated in Orlando, Florida. The eagerly awaited data will shed light on the sustained response of amisulpride, a burgeoning solution for the rescue treatment of pos...

Stock Market Announcement

Eagle Pharmaceuticals Faces Potential Delisting from Nasdaq Due to Failure to File Annual Report

Published Fri, Apr 12 2024 8:06 PM UTC


Woodcliff Lake, N.J., April 12, 2024 - Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) has notified its shareholders that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) on April 8, 2024. The notice advises the Company that it is not in compliance with Nasdaq s listing requirements, specifically Nasdaq Listing Rule 5250...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 1.02
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.05
Price to Sales (Expected) -
Price to Book 0.05
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.18
Working Capital Ratio 2.16
Leverage Ratio (MRQ) 0.61
Total Debt to Equity 0.28
Interest Coverage (TTM) 9.25
Debt Coverage (TTM) 0.83

Per Share Current
Earnings (TTM) 0.91 $
Revenues (TTM) 19.58 $
Cash Flow (TTM) -
Cash 1.17 $
Book Value 19.16 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 2,201,291
Net Income per Employee (TTM) 102,120
Receivable Turnover Ratio (TTM) 2.58
Inventory Turnover Ratio (TTM) 1.48
Asset Turnover Ratio (TTM) 0.68

Profitability Ratios Current
Gross Margin (MRQ) 73.92 %
Operating Margin (MRQ) 15.94 %
Net Margin (MRQ) 7.99 %
Net Cash Flow Margin (MRQ) -10.12 %
Effective Tax Rate (TTM) 59.04 %

Management Effectiveness Current
Return On Assets (TTM) 3.17 %
Return On Investment (TTM) 4.02 %
Return On Equity (TTM) 4.98 %
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.